Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors

被引：101

作者：

Nakata, Masanori ^{[1
]}

Yada, Toshihiko ^{[1
]}

机构：

[1] Jichi Med Sch, Sch Med, Div Integrat Physiol, Dept Physiol, Minami Kawachi, Tochigi 32904, Japan

来源：

REGULATORY PEPTIDES | 2008年 / 145卷 / 1-3期

基金：

日本学术振兴会;

关键词：

cannabinoids; CB1; receptor; insulin; pancreatic beta-cell; calcium oscillation;

D O I：

10.1016/j.regpep.2007.08.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity is the main risk factor for the development of metabolic syndrome. Endogenous cannabinoids act on the cannabinoid type 1 (CB1) receptor, a GPCR, and stimulate appetite via central and peripheral actions, while blockade of CB1 receptor reduces body weight in humans. In this study, we aimed to explore a role of the peripheral endocannabinoid system in insulin secretion, which could be important in the metabolic effects of the cannabinoid-CB1 system. We found that mRNA for CB1 receptor, but not CB2 receptor, was expressed in mouse pancreatic islets using RT-PCR. Immunohistochemical study revealed that CB1 receptor was expressed in beta-cells. Furthermore, anandamide and a CB1 agonist, arachidonylcyclopropylamide (ACPA), inhibited glucose-induced insulin secretion from mouse pancreatic islets. Both anandamide and ACPA inhibited glucose-induced cytosolic Ca2+ oscillation in mouse pancreatic beta-cells. These results demonstrate a novel peripheral action of cannabinoids to inhibit insulin secretion via CB1 receptors. (c) 2007 Elsevier B.V. All rights reserved.

引用

页码：49 / 53

页数：5

共 21 条

[1] The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells [J].

Bensaid, M ;

Gary-Bobo, M ;

Esclangon, A ;

Maffrand, JP ;

Le Fur, G ;

Oury-Donat, F ;

Soubrié, P .

MOLECULAR PHARMACOLOGY, 2003, 63 (04) :908-914

[2] Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle [J].

Bonz, A ;

Laser, M ;

Küllmer, S ;

Kniesch, S ;

Babin-Ebell, J ;

Popp, V ;

Ertl, G ;

Wagner, JA .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 (04) :657-664

[3]

Cota D, 2003, J CLIN INVEST, V112, P423, DOI [10.1172/JCI200317725, 10.1172/JCI17725]

[4] Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia [J].

Despres, JP ;

Golay, A ;

Sjostrom, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2121-2134

[5] Leptin-regulated endocannabinoids are involved in maintaining food intake [J].

Di Marzo, V ;

Goparaju, SK ;

Wang, L ;

Liu, J ;

Bátkai, S ;

Járai, Z ;

Fezza, F ;

Miura, GI ;

Palmiter, RD ;

Sugiura, T ;

Kunos, G .

NATURE, 2001, 410 (6830) :822-825

[6] Activation of the peripheral endocannabinoid system in human obesity [J].

Engeli, S ;

Böhnke, J ;

Feldpausch, M ;

Gorzelniak, K ;

Janke, J ;

Bátkai, S ;

Pacher, P ;

Harvey-White, J ;

Luft, FC ;

Sharma, AM ;

Jordan, J .

DIABETES, 2005, 54 (10) :2838-2843

[7]

GILON P, 1993, J BIOL CHEM, V268, P22265

[8]

Giuffrida A, 2001, J PHARMACOL EXP THER, V298, P7

[9] HU-308:: A specific agonist for CB2, a peripheral cannabinoid receptor [J].

Hanus, L ;

Breuer, A ;

Tchilibon, S ;

Shiloah, S ;

Goldenberg, D ;

Horowitz, M ;

Pertwee, RG ;

Ross, RA ;

Mechoulam, R ;

Fride, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (25) :14228-14233

[10] CANNABINOID RECEPTOR LOCALIZATION IN BRAIN [J].

HERKENHAM, M ;

LYNN, AB ;

LITTLE, MD ;

JOHNSON, MR ;

MELVIN, LS ;

DECOSTA, BR ;

RICE, KC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (05) :1932-1936

← 1 2 3 →